Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 98.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,025 shares of the medical research company's stock after selling 62,335 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC's holdings in Edwards Lifesciences were worth $76,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Abacus Planning Group Inc. raised its position in shares of Edwards Lifesciences by 0.3% during the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock valued at $2,977,000 after buying an additional 140 shares during the period. Bowman & Co S.C. lifted its stake in shares of Edwards Lifesciences by 1.2% in the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock valued at $924,000 after purchasing an additional 148 shares during the last quarter. Moors & Cabot Inc. grew its holdings in shares of Edwards Lifesciences by 0.3% during the 4th quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock worth $4,041,000 after purchasing an additional 152 shares during the period. Quadrant Capital Group LLC increased its position in shares of Edwards Lifesciences by 3.1% during the 4th quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company's stock worth $383,000 after purchasing an additional 156 shares during the last quarter. Finally, Pegasus Asset Management Inc. raised its holdings in Edwards Lifesciences by 0.4% in the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company's stock valued at $3,156,000 after buying an additional 159 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the sale, the chief financial officer now owns 30,387 shares in the company, valued at approximately $2,153,526.69. This represents a 27.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the sale, the vice president now directly owns 47,206 shares of the company's stock, valued at $3,295,450.86. The trade was a 16.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,853 shares of company stock worth $5,163,062. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Stock Up 0.1 %

EW traded up $0.10 on Tuesday, reaching $75.64. The company's stock had a trading volume of 1,073,627 shares, compared to its average volume of 4,975,213. The company has a market capitalization of $44.47 billion, a price-to-earnings ratio of 10.84, a P/E/G ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average of $70.96 and a two-hundred day moving average of $71.16.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter in the prior year, the business posted $0.66 EPS. The company's revenue for the quarter was up 6.2% on a year-over-year basis. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the topic of a number of research reports. Robert W. Baird upped their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. Canaccord Genuity Group increased their price target on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday. Barclays lifted their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Truist Financial dropped their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday, April 11th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $79.45.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.